Home » NICE Rejects Roche’s Kadcyla over Pricing Concerns, but Backs Perjeta
NICE Rejects Roche’s Kadcyla over Pricing Concerns, but Backs Perjeta
The U.K.’s National Institute for Health and Care and Excellence published a final guidance endorsing the use of Roche’s Perjeta, while rejecting the firm’s Kadcyla drug.
The recommendation for Perjeta in breast cancer will stand as long as Roche accepts the agreed-upon discount. The move reverses a May 2016 decision that had rejected the drug, over uncertainties regarding the drug’s long-term benefit and limited trial data.
Kadcyla has been available as a breast cancer treatment in England for nearly three years. However, the availability of the medicine is set to end after NICE said the average price of £90,000 per patient, or about $110,000 USD, was too high.
Upcoming Events
-
21Oct